192 related articles for article (PubMed ID: 20053778)
1. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Alfano RW; Leppla SH; Liu S; Bugge TH; Ortiz JM; Lairmore TC; Duesbery NS; Mitchell IC; Nwariaku F; Frankel AE
Mol Cancer Ther; 2010 Jan; 9(1):190-201. PubMed ID: 20053778
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis.
Alfano RW; Leppla SH; Liu S; Bugge TH; Meininger CJ; Lairmore TC; Mulne AF; Davis SH; Duesbery NS; Frankel AE
Mol Cancer Res; 2009 Apr; 7(4):452-61. PubMed ID: 19372576
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Kim S; Yazici YD; Calzada G; Wang ZY; Younes MN; Jasser SA; El-Naggar AK; Myers JN
Mol Cancer Ther; 2007 Jun; 6(6):1785-92. PubMed ID: 17575107
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.
Alfano RW; Leppla SH; Liu S; Bugge TH; Herlyn M; Smalley KS; Bromberg-White JL; Duesbery NS; Frankel AE
Mol Cancer Ther; 2008 May; 7(5):1218-26. PubMed ID: 18483309
[TBL] [Abstract][Full Text] [Related]
5. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.
Alfano RW; Leppla SH; Liu S; Bugge TH; Duesbery NS; Frankel AE
Cell Cycle; 2008 Mar; 7(6):745-9. PubMed ID: 18245947
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
Liu S; Wang H; Currie BM; Molinolo A; Leung HJ; Moayeri M; Basile JR; Alfano RW; Gutkind JS; Frankel AE; Bugge TH; Leppla SH
J Biol Chem; 2008 Jan; 283(1):529-540. PubMed ID: 17974567
[TBL] [Abstract][Full Text] [Related]
7. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Wilhelm SM; Carter C; Tang L; Wilkie D; McNabola A; Rong H; Chen C; Zhang X; Vincent P; McHugh M; Cao Y; Shujath J; Gawlak S; Eveleigh D; Rowley B; Liu L; Adnane L; Lynch M; Auclair D; Taylor I; Gedrich R; Voznesensky A; Riedl B; Post LE; Bollag G; Trail PA
Cancer Res; 2004 Oct; 64(19):7099-109. PubMed ID: 15466206
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivo.
Huang D; Ding Y; Luo WM; Bender S; Qian CN; Kort E; Zhang ZF; VandenBeldt K; Duesbery NS; Resau JH; Teh BT
Cancer Res; 2008 Jan; 68(1):81-8. PubMed ID: 18172299
[TBL] [Abstract][Full Text] [Related]
9. Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Wunderlich A; Khoruzhyk M; Roth S; Ramaswamy A; Greene BH; Doll D; Bartsch DK; Hoffmann S
J Surg Res; 2013 Dec; 185(2):676-83. PubMed ID: 23845866
[TBL] [Abstract][Full Text] [Related]
10. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor.
Depeille P; Young JJ; Boguslawski EA; Berghuis BD; Kort EJ; Resau JH; Frankel AE; Duesbery NS
Clin Cancer Res; 2007 Oct; 13(19):5926-34. PubMed ID: 17908989
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
Yadav A; Kumar B; Teknos TN; Kumar P
Mol Cancer Ther; 2011 Jul; 10(7):1241-51. PubMed ID: 21551262
[TBL] [Abstract][Full Text] [Related]
13. The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contribution.
Rouleau C; Menon K; Boutin P; Guyre C; Yoshida H; Kataoka S; Perricone M; Shankara S; Frankel AE; Duesbery NS; Vande Woude G; Biemann HP; Teicher BA
Int J Oncol; 2008 Apr; 32(4):739-48. PubMed ID: 18360701
[TBL] [Abstract][Full Text] [Related]
14. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
[TBL] [Abstract][Full Text] [Related]
15. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
Gomez-Rivera F; Santillan-Gomez AA; Younes MN; Kim S; Fooshee D; Zhao M; Jasser SA; Myers JN
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4519-27. PubMed ID: 17671138
[TBL] [Abstract][Full Text] [Related]
16. A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Cohen SM; Mukerji R; Timmermann BN; Samadi AK; Cohen MS
Am J Surg; 2012 Dec; 204(6):895-900; discussion 900-1. PubMed ID: 23231932
[TBL] [Abstract][Full Text] [Related]
17. Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.
Ding Y; Boguslawski EA; Berghuis BD; Young JJ; Zhang Z; Hardy K; Furge K; Kort E; Frankel AE; Hay RV; Resau JH; Duesbery NS
Mol Cancer Ther; 2008 Mar; 7(3):648-58. PubMed ID: 18319331
[TBL] [Abstract][Full Text] [Related]
18. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice.
Abi-Habib RJ; Singh R; Leppla SH; Greene JJ; Ding Y; Berghuis B; Duesbery NS; Frankel AE
Clin Cancer Res; 2006 Dec; 12(24):7437-43. PubMed ID: 17189417
[TBL] [Abstract][Full Text] [Related]
19. Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Sugiyama H; Onuki K; Ishige K; Baba N; Ueda T; Matsuda S; Takeuchi K; Onodera M; Nakanuma Y; Yamato M; Yamamoto M; Hyodo I; Shoda J
J Gastroenterol; 2011 Jun; 46(6):779-89. PubMed ID: 21331764
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Savvides P; Nagaiah G; Lavertu P; Fu P; Wright JJ; Chapman R; Wasman J; Dowlati A; Remick SC
Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]